Does Rallies show 13F holders for DTIL?

Yes. Rallies tracks hedge fund and 13F ownership data for DTIL, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DTIL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DTIL. It does not provide personalized investment advice.

DTIL (Precision BioSciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Precision BioSciences, Inc. Common Stock (DTIL) is a publicly traded Healthcare sector company. As of May 21, 2026, DTIL trades at $7.18 with a market cap of $179.58M and a P/E ratio of -3.32. DTIL moved +3.77% today. Year to date, DTIL is +75.98%; over the trailing twelve months it is +47.13%. Its 52-week range spans $3.53 to $9.81. Analyst consensus is strong buy with an average price target of $36.33. Rallies surfaces DTIL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DTIL stock?

Hedge funds tracked by Rallies that own DTIL include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Precision BioSciences, Inc. Common Stock.

DTIL Key Metrics

Key financial metrics for DTIL
Metric	Value
Price	$7.18
Market Cap	$179.58M
P/E Ratio	-3.32
EPS	$-2.14
Dividend Yield	0.00%
52-Week High	$9.81
52-Week Low	$3.53
Volume	0
Avg Volume	0
Revenue (TTM)	$45.07M
Net Income	$-43.60M
Gross Margin	0.00%

Top Hedge Funds Holding DTIL

Renaissance Technologies holds 109.80K shares of DTIL, changed +36.23% as of Dec 31, 2024.
Citadel Advisors holds 56.40K shares of DTIL, changed -42.02% as of Dec 31, 2024.

Latest DTIL News

Precision BioSciences Expands ELIMINATE-B Trial with France and Romania Sites, Screening Q2 2026 — Apr 15, 2026
Precision BioSciences Secures $7.5M Milestone Payment for MS Therapy Progress — Mar 2, 2026

Recent DTIL Insider Trades

Amoroso Michael sold 20.56K (~$78.95K) on Feb 18, 2026.
Kelly John Alexander sold 8.15K (~$31.29K) on Feb 18, 2026.
Scimeca Dario sold 4.92K (~$18.91K) on Feb 18, 2026.

DTIL Analyst Consensus

3 analysts cover DTIL: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.33.

Common questions about DTIL

Who owns DTIL stock?: Hedge funds tracked by Rallies that own DTIL include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Precision BioSciences, Inc. Common Stock.
Does Rallies show 13F holders for DTIL?: Yes. Rallies tracks hedge fund and 13F ownership data for DTIL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DTIL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DTIL. It does not provide personalized investment advice.